Gunderson Dettmer client Lyndra Therapeutics has entered into a partnership agreement with Gilead Sciences to develop and commercialize ultra-long-acting oral HIV therapies. Gilead with have exclusive rights to Lyndra’s therapeutics platform for ultra-long-acting formulations related to HIV.

In the announcement of the collaboration Lyndra Therapeutics CEO and cofounder Amy Schulman said, “Gilead has led the way in HIV prevention and treatment by focusing on reducing pill burden through the development of single-tablet oral regiments for their therapies, addressing an epidemic that affects nearly 40 million people globally. At Lyndra, our commitment to HIV is foundational and we are delighted to continue to work with strong research and development partners such as the Bill & Melinda Gates Foundation and, now, Gilead.”

The Gunderson Dettmer team representing Lyndra was led by Tim Ehrlich and included Joel Diamond.